Tuesday, August 11, 2009

Astellas Seeks Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications

Astellas Pharma US, Inc. announced today that the U.S. FDA has substantially denied the company's Citizen Petition to ensure the safe and effective use of immunosuppressants used to prevent rejection in organ transplant patients.

The details can be read here.

No comments: